Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 13, Pages -Publisher
MDPI
DOI: 10.3390/ijms23137138
Keywords
lung cancer; NSCLC; tumor-draining vein; exosomes; extracellular vesicles; relapse biomarker; miRNAs; miR-203a-3p
Funding
- AECC-Catalunya
- Ministry of Economy and Competition (MINECO)
- European Union FEDER funds [SAF2017-88606-P]
- SEPAR-AstraZeneca Ayudas Investigacion PII Oncologia 2021
- Becas SEPAR [1326]
- Catedra UB Hospital Clinico de Cancer de Pulmon Astrazeneca
Ask authors/readers for more resources
By analyzing the cargo of extracellular vesicles (EVs) from the tumor-draining vein of the lung, researchers have identified a promising new biomarker (EV-miR-203a-3p) for predicting post-surgical relapse in patients with non-small cell lung cancer (NSCLC).
In resected non-small cell lung cancer (NSCLC), post-surgical recurrence occurs in around 40% of patients, highlighting the necessity to identify relapse biomarkers. An analysis of the extracellular vesicle (EV) cargo from a pulmonary tumor-draining vein (TDV) can grant biomarker identification. We studied the pulmonary TDV EV-miRNAome to identify relapse biomarkers in a two-phase study (screening and validation). In the screening phase, a 17-miRNA relapse signature was identified in 18 selected patients by small RNAseq. The most expressed miRNA from the signature (EV-miR-203a-3p) was chosen for further validation. Pulmonary TDV EV-miR-203a-3p was studied by qRT-PCR in a validation cohort of 70 patients, where it was found to be upregulated in relapsed patients (p = 0.0194) and in patients with cancer spread to nearby lymph nodes (N+ patients) (p = 0.0396). The ROC curve analysis showed that TDV EV-miR-203a-3p was able to predict relapses with a sensitivity of 88% (AUC: 0.67; p = 0.022). Moreover, patients with high TDV EV-miR-203a-3p had a shorter time to relapse than patients with low levels (43.6 vs. 97.6 months; p = 0.00703). The multivariate analysis showed that EV-miR-203a-3p was an independent, predictive and prognostic post-surgical relapse biomarker. In conclusion, pulmonary TDV EV-miR-203a-3p is a promising new relapse biomarker for resected NSCLC patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available